Answers are grounded in this paper and cite their sources.
The failure of drug candidates in clinical development remains a critical issue for the pharmaceutical and biotechnology industries. This article documents those oncology drugs discontinued in 2008 and briefly reviews reasons for termination of development. Source information was derived from a search of the Pharmaprojects database for drugs reaching phase I-III clinical trials.
No takes yet. Share an insight, caveat, or question.
Robert J. Williams (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: